Ignite Creation Date:
2025-12-24 @ 5:30 PM
Ignite Modification Date:
2026-01-13 @ 9:14 AM
Study NCT ID:
NCT06496568
Status:
RECRUITING
Last Update Posted:
2025-12-01
First Post:
2024-07-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-11
Start Date Type:
ACTUAL
Primary Completion Date:
2026-09-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-07-04
First Submit QC Date:
None
Study First Post Date:
2024-07-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-27
Last Update Post Date:
2025-12-01
Last Update Post Date Type:
ESTIMATED